Are There Effects of Renin-Angiotensin System Antagonists Beyond Blood Pressure Control?

American Journal of Cardiology

Volumn 105, Issue 1 SUPPL., 2010, Pages 21A-29A

  Bakris, George ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BRADYKININ; CAPTOPRIL; CARVEDILOL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; LOSARTAN; METOPROLOL; NITRIC OXIDE; OLMESARTAN; PERINDOPRIL; QUINAPRIL; RAMIPRIL; SIMVASTATIN; SUPEROXIDE; TELMISARTAN; TRANDOLAPRIL;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMORBIDITY; CORONARY ARTERY ATHEROSCLEROSIS; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE MARKER; DRUG WITHDRAWAL; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; NEPHROSCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PRIORITY JOURNAL; QT DISPERSION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECONDARY PREVENTION; STROKE; UNSPECIFIED SIDE EFFECT;

EID: 72149123677     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.10.010     Document Type: Article

References (50)

1. Dzau V., and Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 121 (1991) 1244-1263
2. Ruilope L., Kjeldsen S.E., De La Sierra A., Mancia G., Ruggenenti P., Stergious G.S., Bakris G.L., and Giles T.D. The kidney and cardiovascular risk-implications for management: a consensus statement from the European Society of Hypertension. Blood Press 16 (2007) 72-79
3. Muller G., Goettsch C., and Morawietz H. Oxidative stress and endothelial dysfunction. Hamostaseologie 27 (2007) 5-12
4. Zhu Y.C., Zhu Y.Z., Lu N., Wang M.J., Wang Y.X., and Yao T. Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and cardiac remodelling. Clin Exp Pharmacol Physiol 30 (2003) 911-918
5. Koren M.J., Devereux R.B., Casale P.N., Savage D.D., and Laragh J.H. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114 (1991) 345-352
6. Ochodnicky P., Vettoretti S., Henning R.H., Buikema H., Van Dokkum R.P., and de Zeeuw D. Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response. J Nephrol 19 (2006) 246-258
7. Wolf G., and Ziyadeh F.N. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 106 (2007) 26-31
8. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Jones D.W., Materson B.J., Oparil S., Wright Jr. J.T., and Roccella E.J. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
9. Whitworth J.A., and World Health OrganizationInternational Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21 (2003) 1983-1992
10. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., Grassi G., Heagerty A.M., Kjeldsen S.E., Laurent S., et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25 (2007) 1105-1187
11. Biollaz J., Brunner H.R., Gavras I., Waeber B., and Gavras H. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 4 (1982) 966-972
12. Brown M.J. Angiotensin receptor blockers in essential hypertension. Lancet 342 (1993) 1374-1375
13. Kitakaze M., Node K., Takashima S., Minamino T., Kuzuya T., and Hori M. Cellular mechanisms of cardioprotection afforded by inhibitors of angiotensin converting enzyme in ischemic hearts: role of bradykinin and nitric oxide. Hypertens Res 23 (2000) 253-259
14. Allen T.J., Cao Z., Youssef S., Hulthen U.L., and Cooper M.E. Role of angiotensin II and bradykinin in experimental diabetic nephropathy: functional and structural studies. Diabetes 46 (1997) 1612-1618
15. Silverstein R.L., Fenves A.Z., and Ram C.V. ARBs and target organ protection: exploring benefits beyond their antihypertensive effects. Postgrad Med 116 (2004) 31-38 41
16. Linz W., Wiemer G., Schaper J., Zimmermann R., Nagasawa K., Gohlke P., Unger T., and Schölkens B.A. Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis. Mol Cell Biochem 147 (1995) 89-97
17. Scholkens B.A., Linz W., and Martorana P.A. Experimental cardiovascular benefits of angiotensin-converting enzyme inhibitors: beyond blood pressure reduction. J Cardiovasc Pharmacol 18 suppl 2 (1991) S26-S30
18. Stier Jr. C.T., Mahboubi K., DiPippo V.A., Levine S., and Chander P.N. The antiproteinuric action of enalapril in stroke-prone spontaneously hypertensive rats is unrelated to alterations in urinary prostaglandins. J Pharmacol Exp Ther 260 (1992) 1410-1415
19. Okamoto K., Ohta Y., Chikugo T., Shiokawa H., and Morita N. Chronic treatment with captopril, SQ29,852, hydralazine and a 33% fish meal diet in malignant stroke-prone spontaneously hypertensive rats. J Hypertens 9 (1991) 1105-1117
20. Brosnan M.J., Hamilton C.A., Graham D., Lygate C.A., Jardine E., and Dominiczak A.F. Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. J Hypertens 20 (2002) 281-286
21. Strawn W.B., Chappell M.C., Dean R.H., Kivlighn S., and Ferrarion C.M. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 101 (2000) 1586-1593
22. Miyazaki M., and Takai S. Anti-atherosclerotic efficacy of olmesartan. J Hum Hypertens 16 suppl 2 (2002) S7-S12
23. Malmqvist K., Kahan T., Isaksson H., and Ostergren J. Regression of left ventricular mass with captopril and metoprolol, and the effects on glucose and lipid metabolism. Blood Press 10 (2001) 101-110
24. Mitchell G.F., Dunlap M.E., Warnica W., Ducharme A., Arnold J.M., Tardif J.C., Solomon S.D., Domanski M.J., Jablonski K.A., Rice M.M., and Pfeffer M.A. Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy. Hypertension 49 (2007) 1271-1277
25. Braunwald E., Domanski M.J., Fowler S.E., Geller N.L., Gersh B.J., Hsia J., Pfeffer M.A., Rice M.M., Rosenberg Y.D., and Rouleau J.L. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004) 2058-2068
26. Gansevoort R.T., Sluiter W.J., Hemmelder M.H., de Zeeuw D., and de Jong P.E. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 10 (1995) 1963-1974
27. O'Rourke M.F., and Seward J.B. Central arterial pressure and arterial pressure pulse: new views entering the second century after Korotkov. Mayo Clin Proc 81 (2006) 1057-1068
28. Jiang X.J., O 'Rourke M.F., Zhang Y.Q., He X.Y., and Liu L.S. Superior effect of an angiotensin-converting enzyme inhibitor over a diuretic for reducing aortic systolic pressure. J Hypertens 25 (2007) 1095-1099
29. Galzerano D., Tammaro P., del Viscovo L., Lama D., Galzerano A., Broglio R., Tuccillo B., prolisso G., and Caporosso P. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am J Hypertens 18 (2005) 1563-1569
30. Malmqvist K., Kahan T., Edner M., and Bergfeldt L. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA). Am J Cardiol 90 (2002) 1107-1112
31. Makino H., Haneda M., Babazono T., Moriya T., Ito S., Iwamoto Y., Kawamori R., Takeuchi M., and Katayama S. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 30 (2007) 1577-1578
32. Bakris G., Burgess E., Weir M., Davidai G., Koval S., and AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 74 (2008) 364-369
33. Wing L.M., Reid C.M., Ryan P., Beilin L.J., Brown M.A., Jennings G.L., Johnston C.I., McNeil J.J., MacDonald G.J., Marley J.E., Morgan T.O., and West M.J. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348 (2003) 583-592
34. Hilleman D.E., and Lucas Jr. B.D. Angiotensin-converting enzyme inhibitors and stroke risk: benefit beyond blood pressure reduction?. Pharmacotherapy 24 (2004) 1064-1076
35. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G., and Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
36. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
37. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 372 (2008) 1174-1183 Erratum in: Lancet 2008;372:1384
38. The ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluation telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 148 (2004) 52-61
39. Turnbull F., and Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 (2003) 1527-1535
40. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 165 (2005) 1410-1419
41. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D., and Collaborative Study Group. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329 (1993) 1456-1462
42. Wright J.T., Bakris G., Greene T., Agodoa L.Y., Appel L.J., Charleston J., Cheek D., Douglas-Baltimore J.G., Gassman J., Glassock R., et al., African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the ASSK trial. JAMA 288 (2002) 2421-2431
43. Ibsen H., Olsen M.H., Wachtell K., Borch-Johnsen K., Lindholm L.H., Mogensen C.E., Dahlöf B., Snapinn Sm., Wan Y., and Lyle P.A. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy?. The LIFE study. Diabetes Care 29 (2006) 595-600
44. Dahlöf B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pederson O., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
45. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Ritz E., Atkins R.C., Rohde R., and Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
46. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., Remuzzi G., Snapinn S.M., Zhang Z., and Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
47. Kunz R., Friedrich C., Wolbers M., and Mann J.F. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148 (2008) 30-48
48. Mann J.F.E., Schmieder R.E., McQueen M., Dyal L., Schumacher H., Poque J., Wang X., Maggioni A., Budaj A., Chaithiraphan S., et al., ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 372 (2008) 547-553
49. Turnbull F., Neal B., Pfeffer M., Kostis J., Algert C., Woodward M., Chalmers J., Zanchetti A., MacMahon S., and Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 25 (2007) 951-958
50. Verma S., Mamdani M.M., Al-Omran M., Melo M., and Rouleau J. Angiotensin receptor blockers vs angiotensin converting enzyme inhibitors and acute coronary syndrome outcomes in elderly patients: a population-based cohort study (UMPIRE study results). J Am Soc Hypertens 1 (2007) 286-294